People with Duchenne muscular dystrophy have a shorter-than-average life expectancy due to changes in muscles that affect breathing, heart activity, and other functions. However, treatment advances ...

– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings – – Ongoing pivotal trial and FDA Type C meeting provide clear path ...

Craig McDonald, M.D., Professor and Chair, Department of Physical Medicine & Rehabilitation, Professor of Pediatrics, Director MDA Neuromuscular Disease Clinics ...

Capricor Therapeutics announced that the U.S. FDA has granted Orphan Drug Designation to its lead cell therapy candidate, Deramiocel, for the treatment of Becker Muscular Dystrophy (BMD). This ...

People with Duchenne muscular dystrophy (DMD) frequently live well into adulthood. Advances in treatment have significantly increased the life expectancy for this condition. The median life expectancy ...